Invectys is a biotech company proposing immunotherapeutic cancer vaccine targeting the human telomerase.
Invectys – therapeutic cancer vaccine
Cancer is characterized by uncontrolled cell regeneration leading to an immortalization of normal cells. The telomerase plays an important role in the deregulation of the cell physiology. Indeed, 95 % of human cancers express the human telomerase (hTERT). Thus, telomerase is a very attractive target for cancer treatment. Interestingly, the immune system can identify and attack cancer cells: a cancer makes so much telomerase that occasionally the immune system responds to it. Furthermore, the immune system can be educated to identify fragments of proteins made by tumor cells so that killer cells can attack the tumor. Invectys develops products inducing immune responses to telomerase. Invectys technology is based on an exclusive worldwide patent held by the Institut Pasteur to induce immune responses to telomerase. Invectys’ first product is called INVAC1. INVAC1 is fully optimized and has gone through preclinical regulatory toxicology tests, and will soon go to clinical trials. According to Invectys, INVAC1 is probably “the closest thing to a universal cancer vaccine”. The proprietary telomerase gene technology used by Invectys is very cost effective and will help reduce the financial burden linked with many contemporary anti-cancer therapies.
Invectys is a biotech company headquartered in Paris (France). Management Team is composed by Pierre Langlade Demoyen, Simon Wain-Hobson, Abderrahim Lachgar and Thierry Huet. Invectys has a strong pipeline at a discovery stage, and a second major product will start preclinical trials shortly.
More about this biotech company : www.invectys.com